Lannett Company, Inc. (LCI) |
0.5744 -0.002 (-0.28%)
|
08-19 02:04 |
Open: |
0.57 |
Pre. Close: |
0.576 |
High:
|
0.5798 |
Low:
|
0.57 |
Volume:
|
64,107 |
Market Cap:
|
25(M) |
|
|
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
0.59 - 0.59 |
0.59 - 0.59 |
Low:
|
0.57 - 0.57 |
0.57 - 0.57 |
Close:
|
0.57 - 0.58 |
0.58 - 0.58 |
|
Technical analysis |
as of: 2022-08-18 3:54:07 PM |
Overall:
|
|
Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
Target: |
Six months: 0.71 One year: 0.75 |
Support: |
Support1: 0.55 Support2: 0.45 |
Resistance: |
Resistance1: 0.61 Resistance2: 0.64 |
Pivot: |
0.57  |
Moving Average: |
MA(5): 0.58 MA(20): 0.57 
MA(100): 0.6 MA(250): 1.37  |
MACD: |
MACD(12,26): -0.1 Signal(9): -0.1  |
Stochastic oscillator: |
%K(14,3): 26.3 %D(3): 33  |
RSI: |
RSI(14): 47  |
52-week: |
High: 3.82 Low: 0.45 |
Average Vol(K): |
3-Month: 254 (K) 10-Days: 135 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LCI ] has closed above bottom band by 37.0%. Bollinger Bands are 67.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 40 bars. This is a sign that the market may be about to initiate a new trend. |
|
Headline News |
Thu, 18 Aug 2022 Base 2023 BMW X7 LCI With Just One Option Featured On Video - BMWBLOG
Thu, 18 Aug 2022 Is LCI Industries' (NYSE:LCII) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Simply Wall St
Thu, 18 Aug 2022 2024 BMW X5 M Virtually Drops by to Showcase LCI Goodies, Changes Are Subtle - autoevolution
Tue, 16 Aug 2022 LCI sees increased demand, but faces a shortage of airframes - Vertical Magazine
Tue, 16 Aug 2022 LCI Industries (NYSE:LCII) Shares Sold by State Board of Administration of Florida Retirement System - Defense World
Mon, 15 Aug 2022 Short Interest in LCI Industries (NYSE:LCII) Grows By 9.3% - Defense World
|
Financial Analysis |
Price to Book Value: |
Neutral |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Neutral |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Outperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Underperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NYSE |
Sector: Healthcare |
Industry: Drug Manufacturers—Specialty & Generic |
Shares Out. |
43 (M) |
Shares Float |
31 (M) |
% Held by Insiders
|
13.4 (%) |
% Held by Institutions
|
53 (%) |
Shares Short
|
4,400 (K) |
Shares Short P.Month
|
4,390 (K) |
Stock Financials |
EPS
|
-7.9 |
EPS Est Next Qtl
|
0.66 |
EPS Est This Year
|
2.59 |
EPS Est Next Year
|
2.75 |
Book Value (p.s.)
|
-3.93 |
Profit Margin (%)
|
-85 |
Operating Margin (%)
|
-13.8 |
Return on Assets (ttm)
|
-4.5 |
Return on Equity (ttm)
|
0 |
Qtrly Rev. Growth
|
-30.3 |
Gross Profit (p.s.)
|
2.33 |
Sales Per Share
|
8.65 |
EBITDA (p.s.)
|
-0.36 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
39 (M) |
Levered Free Cash Flow
|
42 (M) |
Stock Valuations |
PE Ratio
|
-0.08 |
PEG Ratio
|
-0.1 |
Price to Book value
|
-0.15 |
Price to Sales
|
0.06 |
Price to Cash Flow
|
0.63 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
7 Binary Options
|
Your Ad Here
|
|